Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMbark
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
- NCT02426086 ↗
- Completed
- Geron Corporation
- Focused
We haven't built an HCP commentary report on IMbark (imetelstat in Myelofibrosis) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMbark so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 4 | |
| X threads | 3 | |
| Podcasts | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Myelofibrosis
- Interventions
- Imetelstat 4.7 mg/kg; Imetelstat 9.4 mg/kg
- Arms
- Imetelstat 4.7 mg/kg · Experimental
- Imetelstat 9.4 mg/kg · Experimental
- Enrollment
- 107
- Primary outcomes
- Percentage of Participants With Spleen Response
- Percentage of Participants With Symptom Response
- Sponsor
- Geron Corporation
- Start
- Aug 28, 2015
- Primary completion
- Apr 26, 2018
- Results posted
- Yes
- Registry record
- NCT02426086 · updated Sep 14, 2021
Publications
linked from the registry- Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 Sep 10;39(26):2881-2892. doi: 10.1200/JCO.20.02864. Epub 2021 Jun 17. PubMed 34138638